BRIEF-FDA staff says observed 3 serious risks with NPS' bowel drug

Oct 12 (Reuters) - NPS Pharmaceuticals Inc :

* US FDA staff says observed 3 serious risks with NPS Pharmaceuticals'

teduglutide in short bowel syndrome program

* US FDA staff says NPS' bowel syndrome drug teduglutide warrants a

risk evaluation and mitigation strategy

* Further company coverage((Bangalore Newsroom; +1 646 223 8780))